- Home
- VOR vs SGMT Comparison
VOR vs SGMT Comparison
Compare VOR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VOR | SGMT |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 238.7M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | VOR | SGMT |
|---|---|---|
| Price | $8.13 | $6.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $70.43 | $29.75 |
| AVG Volume (30 Days) | ★ 1.1M | 533.3K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.62 | $1.73 |
| 52 Week High | $65.80 | $11.41 |
Technical Indicators
Market Signals| Indicator | VOR | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 29.79 | 39.50 |
| Support Level | $7.21 | $6.02 |
| Resistance Level | $8.60 | $6.55 |
| Average True Range (ATR) | 0.87 | 0.51 |
| MACD | 0.55 | -0.12 |
| Stochastic Oscillator | 44.80 | 16.67 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.